louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06706557: Analysis of Circulating Tumor DNA (ctDNA) in HER2-low Advanced/Metastatic Breast Cancer
Official title: A Pilot Study on the Analysis of Circulating Tumor DNA (ctDNA) in HER2-low Advanced/Metastatic Breast Cancer
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Advanced Metastatic Breast Cancer
Lead sponsor: European Institute of Oncology
Sponsor class: OTHER
First posted: 2024-11-26
Enrollment: 30
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: advanced/metastatic breast cancer with low levels of HER2 expression (HER2 low)

Brief summary: A Pilot study on circulating tumor DNA (ctDNA) in advanced/metastatic breast cancer with low levels of HER2 expression (HER2 low)

Detailed description: Prospective single-center feasibility study of 30 patients with carcinoma breast with low levels of HER2 expression, defined as 1+ or 2+ expression levels by the IHC technique (immunohistochemistry) and the gene not amplified by the ISH test (in situ hybridization)

Eligibility criteria: Inclusion Criteria

* Participants diagnosed with HER2-low breast cancer, defined as IHC score 1+ or 2+ and not amplified at in situ hybridization (ISH) test as confirmed by local laboratory testing.
* Participants should be at advanced or metastatic setting prior to treatment.
* Written informed consent (Accordo di Partecipazione alla Ricerca Scientifica) and specific informed consent to the study must be signed and dated by the patient and the doctor prior to inclusion.
* Patients must be accessible for follow-up.

Primary outcomes:
measure: circulating tumor DNA (ctDNA) in advanced/metastatic breast cancer with low levels of HER2 expression (HER2 low)
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Milan
country: Italy
facility: European Institute of Oncology
state: MI
Study officials:
affiliation: Istituto Europeo di Oncologia
name: Nicola Fusco, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03685357: Correlation Between Idiopathic Parkinson's Disease and Diabetes Mellitus
Official title: Investigation of the Possible Correlation Between Idiopathic Parkinson's Disease and Diabetes Mellitus in Egyptian Elderly Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Observation
Lead sponsor: Ain Shams University
Sponsor class: OTHER
Collaborators: name: Al-Azhar University
First posted: 2018-09-26
Enrollment: 120
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Egyptian Elderly

Brief summary: Correlation between Idiopathic Parkinson's disease and diabetes mellitus in Egyptian Elderly Patients

Detailed description: 1. Record RBDSQ ("Rapid eye movement Sleep" Behavior Disorder Screening Questionnaire) total score difference between Group 1 and Group 2 .
2. Oral glucose tolerance test will be performed and compared between Group 3 and Group 4.
3. Association between glucose level and motor complication of L-dopa among Idiopathic Parkinson's patients using Unified Parkinson's Disease Rating Scale (UDPRS).

Eligibility criteria: Inclusion Criteria:

1. Diabetic Patients
2. Idiopathic Parkinsonism

Exclusion Criteria:

1. Secondary Parkinsonism due to stroke, trauma and encephalitis.
2. Drug induced Parkinsonism.

Primary outcomes:
measure: UPDRS (Unified Parkinson's Disease Rating) Scale)
timeFrame: Baseline
measure: Oral Glucose Tolerance Test
timeFrame: 0, 0.5 hour , 1 hour, 1.5 hour , 2 hour
measure: RBDSQ ("Rapid eye movement Sleep" Behavior Disorder Screening Questionnaire)
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: AinShams University
Study officials:
affiliation: AinShams University
name: Afnan Elgnainy
role: PRINCIPAL_INVESTIGATOR
References:
citation: AwadAllah Elgnainy A, Hamed MI, Osman Mohamed W, Sabri NA. Investigation of the Possible Correlation between Idiopathic Parkinson's Disease and Diabetes Mellitus in Egyptian Patients: A Pilot Study. Neurol Res Int. 2021 Nov 12;2021:2838669. doi: 10.1155/2021/2838669. eCollection 2021.
Clinical trial NCT03541057: Vienna Vascular Liver Disease Study
Official title: Vienna Vascular Liver Disease Study: Characterization of Patients With Vascular Liver Disease - a Registry With Biobank
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Vascular Liver Disease
Portal Vein Thrombosis
Budd-Chiari Syndrome
Non-Cirrhotic Portal Hypertension
Rendu Osler Weber
Cardiac Cirrhosis
Porto-sinusoidal Vascular Disorder
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2018-05-30
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All consecutive patients with a vascular liver disease (as specified above) presenting at the outpatient department / inpatient ward of the Medical University of Vienna.

Brief summary: The aim of this Register Trial is to systematically study the epidemiology, risk factors, liver function as well prognosis of patients with vascular liver diseases. Furthermore, important clinical parameters will be assessed in order to evaluate patients' coagulation status and in order to develop new biomarkers derived from blood, urine, stool or ascites of patients as well as histological samples from the upper / lower GI-tract or the liver in order to better understand the natural history of vascular liver diseases.

Detailed description: We will include patients with vascular liver diseases, including

* portal vein thrombosis (PVT)
* Budd-Chiari Syndrome (BCS)
* Heredetary Hemorrhagic Teleangiectasia (HHT, or Osler-Rendu Disease)
* Noncirrhotic-portal hypertension (NCPH) and Porto-sinusoidal vascular disorder
* Cirrhosis cardiaque if the fulfill inclusion/exclusion criteria and provide written informed consent. Participation in the biobank is optional for the patients. In particular, we will study the natural course of the patients in regard to hepatic decompensation (ascites, variceal bleeding, hepatic encephalopathy), need for intensified treatment (TIPS, ICU, liver transplantation) and survival.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of a vascular liver disease by imaging (sonography, CT, MRI), transient elastography or liver histology
* PVT: Portal vein thrombosis
* NCPH: non-cirrhotic Portal Hypertension
* PSVD: porto-sinusoidal vascular disorder
* BCS: Budd-Chiari-Syndrome
* SOS: sinusoidal occlusive disease
* HHT: hereditary hemorrhagic teleangiectasia
* CIRCAD: cirrhosis cardiaque
* Age \>18 years and \<100 years
* Written informed consent obtained

Exclusion Criteria:

- withdrawal of written informed consent

Primary outcomes:
measure: Hepatic Decompensation
timeFrame: Up to 10 years (=Study Period)
Secondary outcomes:
measure: Liver-related death
timeFrame: Up to 10 years (=Study Period)
measure: Coagulation status
timeFrame: Up to 10 years (=Study Period)
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Medical University of Vienna
Study officials:
References:
Clinical trial NCT02122757: Anodal Transcranial Direct Current Stimulation of the Visual Cortex Versus Sham Stimulation in the Episodic Migraine
Official title: Randomised Sham-controlled Trial of Anodal Transcranial Direct Current Stimulation (tDCS) for the Prevention of Episodic Migraine
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Sporadic Migraine
Lead sponsor: University of Liege
Sponsor class: OTHER
First posted: 2014-04-25
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Anodal tDCS increases the excitability of the cerebral cortex and its daily application during intercritical phase, may have a therapeutic effect in episodic migraine.

Detailed description: During the interictal phase, the cerebral cortex is characterised by hyperresponsiveness to repeated sensory stimuli, manifested by a lack of habituation or adaptation of cortical evoked responses. Such habituation deficit can be shown in the visual cortex by the study of visual evoked potentials (VEP) and it is possibly explained by a reduction in the cortical pre-activation level due to thalamo-cortical dysrhythmia. In healthy subjects and in migraineurs between attacks, anodal tDCS increases VEP habituation and 1st block amplitude. In a proof-of-concept trial, the investigators have shown in 10 episodic migraine without aura patients that 2 weekly 15-minute sessions for 8 weeks of anodal tDCS over the visual cortex significantly decreased attack frequency, migraine days, attack duration and acute medication intake for more than 4 weeks after the last treatment session.

This randomized trial was designed to prove the preventive effect in episodic migraine of anodal tDCS over the visual cortex compared to sham stimulation.

Eligibility criteria: Inclusion Criteria:

* diagnosis of episodic migraine with (ICHD III beta 1.2.1) or without aura (ICHD III beta 1.1)

Exclusion Criteria:

* preventive treatment
* others diseases or contraindications to tDCS (epilepsy, pacemaker, metal prosthetics)

Primary outcomes:
measure: Migraine frequency
timeFrame: 6 months
Secondary outcomes:
measure: Migraine intensity
timeFrame: 6 months
measure: Acute medication intake
timeFrame: 6 months
measure: Attack duration
timeFrame: 6 months
measure: Score on psychological scales
timeFrame: 6 Months
Other outcomes:
Locations:
city: Liege
country: Belgium
facility: Roberta Baschi
Study officials:
affiliation: University of Liege
name: Delphine Magis, MD,PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Liege
name: Jean Schoenen, MD,PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05483257: Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma
Official title: Molecular Subtyping Based on Specific HLA-I Genotypes for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma: A Retrospective Observational Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pancreatic Cancer Resectable
Keywords: human leukocyte antigen class I
supertypes
recurrence
Lead sponsor: Ruijin Hospital
Sponsor class: OTHER
Collaborators: name: GeneCast Biotechnology Co., Ltd.
First posted: 2022-08-02
Enrollment: 226
Sex: ALL
Minimum age (years): 34
Maximum age (years): 84
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Radically resected patients with pancreatic adenocarcinoma

Brief summary: Pancreatic adenocarcinoma (PAAD) patients following surgeries are prone to relapse shortly, while it is not well understood by current biomarkers. Given the potential associations of human leukocyte antigen class I (HLA-I) genotype with oncogenic mutational profile and immunotherapy efficacy, we aimed to assess whether differential HLA-I genotype could predict the postoperative outcomes in resected PAAD patients.


Eligibility criteria: Inclusion Criteria:

* Radically resected pancreatic adenocarcinoma (stage I-III)
* Resected tumor tissues and matched blood cells available
* Signed informed consent

Exclusion Criteria:

* Pancreatic cancer except pancreatic adenocarcinoma
* Non-radical resection

Primary outcomes:
measure: Disease-free survival (DFS)
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Ruijin Hospital
state: Shanghai
Study officials:
References:
Clinical trial NCT00376857: Surgical Removal of Idiopathic Epiretinal Membrane With and Without the Assistance of Indocyanine Green.
Official title: Surgical Removal of Idiopathic Epiretinal Membrane With and Without the Assistance of Indocyanine Green: a Randomised Controlled Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Idiopathic Epiretinal Membrane, Cataract
Keywords: Indocyanine green, toxicity, epiretinal membrane, visual field defect
Lead sponsor: University of Regensburg
Sponsor class: OTHER
First posted: 2006-09-15
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: It was the aim of the present study to prospectively compare the functional and morphological outcome of idiopathic epiretinal membrane surgery with and without the assistance of Indocyanine green (ICG). The main outcome measure was improvement of best-corrected visual acuity (BCVA). This was treated as an open question and we had no hypothesis which of the two therapies was superior.


Eligibility criteria: Inclusion Criteria:

* Patients with IEM and cataract or posterior chamber intraocular lens pseudophakia complaining of loss of visual acuity and metamorphopsia during the past six months.

Exclusion Criteria:

* Other retinal disease, non-idiopathic epiretinal membrane, glaucoma or history of retinal detachment.

Primary outcomes:
measure: The main outcome measure was improvement of best-corrected visual acuity (BCVA).
Secondary outcomes:
measure: Other outcome measures included postoperative BCVA, status of Amsler grid test, reduction of macular retinal thickness, residual or recurrent macular epiretinal membrane
Other outcomes:
Locations:
city: Regensburg
country: Germany
facility: Dept. of Ophthalmology, University of Regensburg
Study officials:
affiliation: Dept. of Ophthalmology, University of Regensburg
name: Jost Hillenkamp, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Dept. of Ophthalmology, University of Regensburg
name: Parykshit Saikia, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Dept. of Ophthalmology, University of Regensburg
name: Helmut G Sachs, MD
role: STUDY_CHAIR
References:
citation: Hillenkamp J, Saikia P, Herrmann WA, Framme C, Gabel VP, Sachs HG. Surgical removal of idiopathic epiretinal membrane with or without the assistance of indocyanine green: a randomised controlled clinical trial. Graefes Arch Clin Exp Ophthalmol. 2007 Jul;245(7):973-9. doi: 10.1007/s00417-006-0485-1. Epub 2006 Dec 21.
Clinical trial NCT00514657: Trial in Periodontal Tissue Regeneration Using Fibroblast Growth Factor-2
Official title: Trial in Periodontal Tissue Regeneration Using Fibroblast Growth Factor-2 (Randomised Controlled Phase II Clinical Trial)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Periodontitis
Lead sponsor: Kaken Pharmaceutical
Sponsor class: INDUSTRY
First posted: 2007-08-10
Enrollment: 91
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The present clinical trial clarified that basic fibroblast growth factor-2 (FGF-2) can induce regeneration of periodontal tissue lost by progression of periodontitis and evaluated the safety of such induction.


Eligibility criteria: Inclusion Criteria:

* diagnosed as 2- or 3-walled vertical intrabony defect \>=3 mm deep from the top of the remaining alveolar bone
* with mobility of the tooth of degree 2 or less
* with width of attached gingiva appropriate for Guided Tissue Regeneration

Exclusion Criteria:

* concomitant administration of adrenal cortical steroid within 4 wks after the surgery
* administeration of calcium antagonist during the 4 weeks preceding administration of the investigational drug
* coexisting malignant tumour or history of the same
* coexisting diabetes (HbA1C \>= 6.5%)
* an extremely poor nutritional condition (serum albumin concentration \<2 g/dL)
* pregnancy or lactation

Primary outcomes:
measure: rate of increase in alveolar bone height
timeFrame: 36 weeks after administration
measure: clinical attachment level (CAL) regained
timeFrame: 36 weeks after administration
Secondary outcomes:
measure: time course of rate of increase in alveolar bone height
timeFrame: within 36 weeks after administration
measure: time course of CAL regained
timeFrame: within 36 weeks after administration
measure: the other periodontal inspections (PD, BOP, GI etc.)
timeFrame: within 36 weeks after administration
Other outcomes:
Locations:
Study officials:
affiliation: Kaken Pharmaceutical Co., Ltd.
name: Makoto Tamura, Ph.D
role: STUDY_DIRECTOR
References:
citation: Kitamura M, Nakashima K, Kowashi Y, Fujii T, Shimauchi H, Sasano T, Furuuchi T, Fukuda M, Noguchi T, Shibutani T, Iwayama Y, Takashiba S, Kurihara H, Ninomiya M, Kido J, Nagata T, Hamachi T, Maeda K, Hara Y, Izumi Y, Hirofuji T, Imai E, Omae M, Watanuki M, Murakami S. Periodontal tissue regeneration using fibroblast growth factor-2: randomized controlled phase II clinical trial. PLoS One. 2008 Jul 2;3(7):e2611. doi: 10.1371/journal.pone.0002611.
Clinical trial NCT00149357: Fetal Loss in Women With Unprovoked Thromboembolism (FLUTE)
Official title: Determining the Risk of Fetal Loss in Women With Unprovoked Venous Thromboembolism (VTE) Who Do NOT Have Identifiable Inherited Thrombophilia Compared With Women Who Have the Diagnosis of VTE Excluded
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Venous Thromboembolism
Fetal Death
Keywords: venous thromboembolism
VTE
thrombophilia
fetal loss
Lead sponsor: McMaster University
Sponsor class: OTHER
Collaborators: name: Canadian Institutes of Health Research (CIHR)
First posted: 2005-09-08
Enrollment: 239
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: OTHER

Brief summary: The purpose of this study is to determine the risk of fetal loss in women with unprovoked venous thromboembolism (VTE) who do not have identifiable inherited thrombophilia compared with women who have the diagnosis of venous thromboembolism (VTE) excluded.


Eligibility criteria: Inclusion Criteria:

* Female
* At least 18 years of age
* Symptomatic for unprovoked venous thromboembolism (deep vein thrombosis \[DVT\] or pulmonary embolism \[PE\])
* At least one pregnancy not terminated intentionally

Exclusion Criteria:

* Previous VTE in patients with current VTE excluded

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Clayton
country: Australia
facility: Monash Medical Centre
state: Victoria
city: Hamilton
country: Canada
facility: Hamilton General Hospital
state: Ontario
city: Hamilton
country: Canada
facility: McMaster University Medical Centre
state: Ontario
city: Hamilton
country: Canada
facility: St. Joseph's Hospital
state: Ontario
city: Hamilton
country: Canada
facility: Henderson Research Centre
state: Ontario
Study officials:
affiliation: McMaster University; Department of Medicine
name: Huyen Tran, M.D.
role: STUDY_CHAIR
affiliation: McMaster University; Department of Medicine
name: Jeffrey Ginsberg, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: McMaster University; Department of Medicine
name: Clive Kearon, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: McMaster University; Dept. of Clinical Epidemiology & Biostatistics
name: Jim Julian, M.Math
role: PRINCIPAL_INVESTIGATOR
affiliation: McMaster University; Division of Obstetrics and Gynecology
name: Val Mueller, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01022957: Nephronophthisis : Clinical and Genetic Study
Official title: Characterization and Analysis of Long-term Evolution of Renal and Extra-renal Damages in the Course of Nephronophthisis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Nephronophthisis
Keywords: extra renal damages
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2009-12-01
Enrollment: 150
Sex: ALL
Minimum age (years): 7
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: to describe evolution of Nephronophthisis

Detailed description: To specify the long term evolution of Nephronophthisis in terms of renal disease as well as extra-renal damages for patients having a confirmed diagnosis of NPHP1, NPHP2, NPHP3, NPHP4, NPHP5, NPHP6 or NPHP8 gene mutation

Eligibility criteria: Inclusion Criteria:

* NPHP1, NPHP2, NPHP3, NPHP4, NPHP5, NPHP6 or NPHP8 gene mutation
* 7 years old and older

Exclusion Criteria:

* MRI contra-indications

Primary outcomes:
measure: to determine the long term evolution of Nephronophthisis in terms of renal disease as well as extra-renal damages for patients having a confirmed diagnosis of NPHP1, NPHP2, NPHP3, NPHP4, NPHP5, NPHP6 or NPHP8 gene mutation
timeFrame: start from the first time of clinical diagnosis to now
Secondary outcomes:
measure: to study siblings to anticipate clinical complications (renal and extra-renal damages) of Nephronophthisis
Other outcomes:
Locations:
city: Paris
country: France
facility: Hopital Necker
Study officials:
affiliation: Assistance Publique - Hôpitaux de Paris
name: Rémi SALOMON, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02328157: Combined 25-gauge Vitrectomy and Cataract Surgery With Toric Intraocular Lens With Idiopathic Epiretinal Membrane.
Official title: Combined 25-gauge Vitrectomy and Cataract Surgery With Toric Intraocular Lens With Idiopathic Epiretinal Membrane.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cataract
Epiretinal Membrane
Corneal Astigmatism
Lead sponsor: Kagawa University
Sponsor class: OTHER
First posted: 2014-12-31
Enrollment: 30
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Toric intraocular lens (IOL) is now widely used for the cataract surgery with preoperative corneal astigmatism.

Symptomatic epiretinal membrane (ERM) is often treated with 25-gauge transconjunctival sutureless vitrectomy, resulting in good visual recovery. So far, however, limited information is available on the the stability of axis rotation, astigmatism correction, and improvement in uncorrected distance visual acuity, using astigmatism-correcting IOL in a 25-gauge transconjunctival sutureless vitrectomy combined with cataract surgery. In the current study, eyes with a preoperative corneal cylinder of more than 0.75 diopter had a triple procedure for idiopathic ERM using a toric IOL. Outcome measures will be the amount of IOL axis rotation, uncorrected visual acuity, corrected distance visual acuity, and corneal and refractive astigmatism up to 6 months postoperatively. We are expecting to show that postoperative IOL axis stability is similar to that reported for cataract surgery alone in vitrectomy (triple procedure) for idiopathic ERM with a toric IOL.


Eligibility criteria: Inclusion Criteria:

* Preoperative corneal cylinder of more than 0.75 diopter
* Symptomatic idiopathic epiretinal membrane
* Symptomatic cataract

Exclusion Criteria:

* Severe media opacity other cataract
* Eyes with other retinal disease, such as diabetic retinopathy, retinal vein occlusion, rhegmatogenous retinal detachment

Primary outcomes:
measure: The degree of IOL axis rotation from the end of surgery
timeFrame: Six months after the inplantation
Secondary outcomes:
Other outcomes:
Locations:
city: Miki
country: Japan
facility: Kagawa University Faculty of Medicine
state: Kagawa
Study officials:
affiliation: Kagawa Univerisity Faculty of Medicine
name: AKITAKA TSUJIKAWA, MD
role: PRINCIPAL_INVESTIGATOR
References: